top of page
Benjamin Boettner
22 Jun 2022
The startup will develop and commercialize cost-effective, highly sensitive and specific point-of-care diagnostics, applying a novel electrochemical sensor platform created at the Wyss Institute
(BOSTON) — Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cambridge-based StataDX Inc. announced that the Wyss Institute’s affinity-based, multiplexed, electrochemical sensing technology, eRapid, has been licensed to the startup. The license, coordinated by Harvard’s Office of Technology Development (OTD), grants Stata DX exclusive worldwide access to the eRapid technology in the fields of neurological, cardiovascular, and renal diseases
bottom of page